Abpro Holdings (ABPO) Other Accumulated Expenses (2023 - 2026)
Abpro Holdings' (ABPO) quarterly Other Accumulated Expenses came in at $722000.0 in Q1 2026, down 26.55% YoY from $983000.0 in Q1 2025, and down 32.14% on a QoQ basis from $1.1 million in Q4 2025.
Abpro Holdings (ABPO) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 4 years of Other Accumulated Expenses data on file, last reported at $722000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 26.55% year-over-year to $722000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $722000.0 (down 26.55% YoY) and the FY2025 annual result came in at $1.1 million, up 23.01% from the prior year.
- Other Accumulated Expenses eased to $722000.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.3 million in Q3 2024 to a low of $590000.0 in Q4 2023.
- A 4-year average of $1.3 million and a median of $1.0 million in 2025 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 46.61% — and 2025, when it tumbled 55.33%.
- Tracing ABPO's Other Accumulated Expenses over 4 years: stood at $590000.0 in 2023, then soared by 46.61% to $865000.0 in 2024, then climbed by 23.01% to $1.1 million in 2025, then plunged by 32.14% to $722000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $722000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 722,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 983,000.00 |
| Dec 31, 2024 | 865,000.00 |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | 1.71 Mn |
| Dec 31, 2023 | 590,000.00 |